No Detail Found!

Role of Ondansetron in Reducing Methotrexate Intolerance in Patients with In ammatory Arthritis

Author(s)
Saba Saif Department of Medicine, CMH Lahore Medical College and Institute of Dentistry, Lahore Cantt, Pakistan
Spenta Kakalia Department of Pediatrics, CMH Lahore Medical College and Institute of Dentistry, Lahore Cantt, Pakistan
Rizwana Kitchlew Department of Medicine, CMH Lahore Medical College and Institute of Dentistry, Lahore Cantt, Pakistan
Haseeb Ahmed Khan Department of Medicine, Al-Aleem Medical College Gulab Devi Hospital, Lahore, Pakistan
Samina Fida Department of Medicine, CMH Lahore Medical College and Institute of Dentistry, Lahore Cantt, Pakistan
Muhammad Siddique Department of Medicine, CMH Lahore Medical College and Institute of Dentistry, Lahore Cantt, Pakistan
Abstract
Objective: To determine the frequency of intolerance to Methotrexate (MTX) in patients with in ammatory arthritis by using MTX intolerance severity score, and evaluate the e ects of Ondansetron in reducing MTX intolerance. Study Design: Interventional study. Place and Duration of Study: Rheumatology clinic, Combined Military Hospital (CMH), Lahore, from 1st November 2021 to 30th April 2022. Methodology: Patients with in ammatory arthritis taking methotrexate regularly for>3 months participated in the study. The patients age, gender, education level, marital status and smoking history were documented. The disease duration and disease activity was also recorded. Dose/duration/route/frequency and timing of MTX were noted. MTX intolerance was calculated with the use of the Methotrexate intolerance severity score (MISS) questionnaire. Those MTX intolerant patients who reported nausea and vomiting were prescribed ondansetron along with MTX and were followed up for the next 3 consecutive months. Results: Out of 181 patients, 48(26.5%) showed methotrexate intolerance. The predominant symptom was nausea after taking MTX reported in 93.8% of the MTX intolerant patients followed by behavioural symptoms including restlessness and irritability reported among 79% and 77% of intolerant patients respectively. Those methotrexate intolerant patients who mainly had complaints of nausea and vomiting were started on ondansetron on the day of methotrexate and showed a signi cant reduction in the median of MISS score in the following two consecutive months (p <0.05) while at 3 months the median did not show further reduction as compared to second month (p=0.12). Conclusion: Ondansetron prescribed along with methotrexate in patients having complaints of nausea and vomiting with MTX, reduces the intolerance significantly.
Publication Details
Page(s) 1308-1312
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 32, Issue: 10, Year: 2022

Request the full text from PASTIC

Keywords
Methotrexate, Rheumatoid Arthritis, Ondansetron, Nausea, Arthritis juvenile
0

Citations

0

Downloads

57

Views